Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 64
- Registration Number
- NCT03766425
- Locations
- 🇵🇱
Medical University of Lublin, Lublin, Lubelskie, Poland
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 29
- Registration Number
- NCT03658304
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
- Conditions
- Stage II Ureter Cancer AJCC v8Stage II Urethral Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8Bladder Carcinoma Infiltrating the Muscle of the Bladder WallStage II Bladder Cancer AJCC v8Stage III Ureter Cancer AJCC v8Stage III Urethral Cancer AJCC v8Urethral Urothelial CarcinomaStage II Renal Pelvis Cancer AJCC v8Stage III Bladder Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 2
- Registration Number
- NCT03617913
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Holy Name Medical Center, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03604653
- Locations
- 🇺🇸
Holy Name Medical Center, Teaneck, New Jersey, United States
Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C
- Conditions
- Interventions
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 53
- Registration Number
- NCT03506542
Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT03381352
- Locations
- 🇨🇳
Chinese academy of medical sciences, Beijing, Beijing, China
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Jørgen Bjerggaard Jensen
- Target Recruit Count
- 120
- Registration Number
- NCT03348969
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT03330028
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Prospective Study to Evaluate the Raindrop Near Vision Inlay With Mitomycin C
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Fichte, Endl & Elmer Eyecare
- Target Recruit Count
- 40
- Registration Number
- NCT03242317
- Locations
- 🇺🇸
Fichte Endl & Elmer Eyecare, Amherst, New York, United States
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2017-07-14
- Lead Sponsor
- Whitten Laser Eye
- Target Recruit Count
- 40
- Registration Number
- NCT03126877
- Locations
- 🇺🇸
Whitten Laser Eye, Washington, D.C., District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.